224 related articles for article (PubMed ID: 9192661)
21. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
22. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
23. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
24. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
25. Cell-based vaccines for the stimulation of immunity to metastatic cancers.
Ostrand-Rosenberg S; Pulaski BA; Clements VK; Qi L; Pipeling MR; Hanyok LA
Immunol Rev; 1999 Aug; 170():101-14. PubMed ID: 10566145
[TBL] [Abstract][Full Text] [Related]
26. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
Qi L; Ostrand-Rosenberg S
Traffic; 2000 Feb; 1(2):152-60. PubMed ID: 11208095
[TBL] [Abstract][Full Text] [Related]
27. Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation.
Laufer TM; Smiley ST; Ranger A; Clements VK; Ostrand-Rosenberg S; Glimcher LH
J Immunol; 1997 Dec; 159(12):5914-20. PubMed ID: 9550388
[TBL] [Abstract][Full Text] [Related]
28. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
29. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
Ostrand-Rosenberg S; Thakur A; Clements V
J Immunol; 1990 May; 144(10):4068-71. PubMed ID: 2332639
[TBL] [Abstract][Full Text] [Related]
30. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
31. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
32. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.
Ostrand-Rosenberg S; Clements VK; Thakur A; Cole GA
J Immunogenet; 1989; 16(4-5):343-9. PubMed ID: 2639907
[TBL] [Abstract][Full Text] [Related]
33. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.
Clements VK; Baskar S; Armstrong TD; Ostrand-Rosenberg S
J Immunol; 1992 Oct; 149(7):2391-6. PubMed ID: 1527384
[TBL] [Abstract][Full Text] [Related]
34. Parasite Manipulation of the Invariant Chain and the Peptide Editor H2-DM Affects Major Histocompatibility Complex Class II Antigen Presentation during Toxoplasma gondii Infection.
Leroux LP; Nishi M; El-Hage S; Fox BA; Bzik DJ; Dzierszinski FS
Infect Immun; 2015 Oct; 83(10):3865-80. PubMed ID: 26195549
[TBL] [Abstract][Full Text] [Related]
35. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice.
Yim JH; Wu SJ; Casey MJ; Norton JA; Doherty GM
J Immunol; 1997 Feb; 158(3):1284-92. PubMed ID: 9013971
[TBL] [Abstract][Full Text] [Related]
36. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.
Lu X; Wu S; Blackwell CE; Humphreys RE; von Hofe E; Xu M
Immunology; 2007 Feb; 120(2):207-16. PubMed ID: 17116173
[TBL] [Abstract][Full Text] [Related]
37. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
[TBL] [Abstract][Full Text] [Related]
38. The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability.
Lazarski CA; Chaves FA; Sant AJ
J Exp Med; 2006 May; 203(5):1319-28. PubMed ID: 16682499
[TBL] [Abstract][Full Text] [Related]
39. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
40. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
Tüting T; DeLeo AB; Lotze MT; Storkus WJ
Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]